CytRx (CYTR) to Present Global Phase 2b Clinical Data for Aldoxorubicin at Annual Connective Tissue Oncology Society Meeting
Oncology-focused biopharmaceutical research and development company CytRx Corporation announced it will present additional preliminary data from its Phase 2b clinical trial – demonstrating aldoxorubicin’s potential advantage over doxorubicin in treating soft tissue sarcoma (STS) – at the 18th Annual Connective Tissue Oncology Society (CTOS) Meeting, taking place Thursday, Oct. 31 in the Sheraton New York Times Square Hotel. CytRx previously reported that patients in the trial who were treated with aldoxorubicin had an overall response rate (ORR) of 22 percent, as opposed to those administered the widely used chemotherapeutic agent doxorubicin, who had an ORR of 0 percent. CytRx plans…